Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €29.67 EUR
Change Today +1.91 / 6.88%
Volume 342.5K
ALCLS On Other Exchanges
As of 11:35 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

cellectis (ALCLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - €40.70
52 Week Low
05/27/14 - €5.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLECTIS (ALCLS)

Related News

No related news articles were found.

cellectis (ALCLS) Related Businessweek News

No Related Businessweek News Found

cellectis (ALCLS) Details

Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company’s products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.

89 Employees
Last Reported Date: 03/26/15
Founded in 1999

cellectis (ALCLS) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €328.4K
Co-Founder, Executive Vice President of Corpo...
Total Annual Compensation: €248.8K
Compensation as of Fiscal Year 2013.

cellectis (ALCLS) Key Developments

Cellectis S.A. Appoints New Director, Mr. Jean-Marie Messier

The Combined General Shareholders' Meeting of Cellectis S.A. was held on May 18, 2015. At the meeting, the shareholders have appointed a new Director, Mr. Jean-Marie Messier. Jean-Marie Messier, 58 years old, is co-founder and head of Messier Maris & Associes.

Cellectis S.A. Proposes Amendment of the Articles of Association

Cellectis S.A. announced that at the extraordinary general meeting to be held on May 18, 2015, proposes amendment of article 18 of the company's articles of association.

Cellectis S.A., Annual General Meeting, May 18, 2015

Cellectis S.A., Annual General Meeting, May 18, 2015. Location: 11 rue Watt. Agenda: To consider the board of directors' management report and presentation by the board of directors of the annual financial statements for the fiscal year ended December 31, 2014 and the statutory auditors' reports on the consolidated financial statements for the fiscal year ended December 31, 2014; to consider the allocation of income for the fiscal year ended December 31,2014; to review of the related party transaction; to consider reappointment of directors; to consider the approval of the regulations pertaining to the stock option or stock purchase plan adopted by the board of directors on March 24, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCLS:FP €29.67 EUR +1.91

ALCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $27.68 USD -0.04
Lonza Group AG SFr.133.80 CHF -0.40
Sigma-Aldrich Corp $139.08 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCLS Industry Range
Price/Earnings 100.0x
Price/Sales 30.0x
Price/Book 13.2x
Price/Cash Flow 47,648.6x
TEV/Sales 31.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTIS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at